SCHEMBL20239282

SCHEMBL20239282

O=C(O)NCCc1ccc(Oc2cc(CNc3ncc(Cl)cn3)ncn2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP2K7 O14733 8/20 0.44
DGAT2 Q96PD7 1/20 0.42
LTA4H P09960 1/20 0.40
EPHX2 P34913 1/20 0.40
ACACB O00763 1/20 0.40
PLAAT3 P53816 2/20 0.39
PLAAT5 Q96KN8 2/20 0.39
PLAAT2 Q9NWW9 2/20 0.39
PLAAT4 Q9UL19 2/20 0.39
HDAC3 O15379 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC2 Q92769 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
ADRB1 P08588 1/20 0.38
ADRB3 P13945 1/20 0.38
OPRM1 P35372 4/20 0.38
OPRD1 P41143 4/20 0.38
OPRK1 P41145 4/20 0.38
GRIN2D O15399 1/20 0.38
GRIN3B O60391 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20259228 0.87 LMNA (0.41) MAP2K7DGAT2ACACB
SCHEMBL20239244 0.86 DGAT2 (0.48) DGAT2LTA4HEPHX2ACACBPLAAT3
SCHEMBL20239165 0.85 DGAT2 (0.47) DGAT2LTA4HEPHX2ACACBPLAAT3
SCHEMBL18249766 0.85 PLAAT3 (0.44) MAP2K7LTA4HEPHX2ACACBPLAAT3
SCHEMBL20239305 0.83 DGAT2 (0.49) MAP2K7DGAT2HDAC3HDAC1HDAC2
SCHEMBL20259122 0.83 DGAT2 (0.45) MAP2K7DGAT2GRIN1GRIN2BCYP3A4
SCHEMBL20239174 0.81 LOXL2 (0.53) MAP2K7EPHX2ACACBPLAAT3PLAAT5
SCHEMBL20259192 0.80 DGAT2 (0.47) DGAT2ACACBPLAAT3PLAAT5PLAAT2
SCHEMBL20239232 0.78 DGAT2 (0.46) DGAT2LTA4HEPHX2ACACBPLAAT3
SCHEMBL20239177 0.77 DGAT2 (0.49) DGAT2ACACBPLAAT3PLAAT5PLAAT2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3298001-B1 DGAT2 INHIBITORS LILLY CO ELI (US) 2020-05-13 EP disclosed
US-10053429-B2 DGAT2 inhibitors ELI LILLY AND COMPANY (US) 2018-08-21 US disclosed
US-20180162825-A1 NOVEL DGAT2 INHIBITORS ELI LILY AND COMPANY (US) 2018-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180162825-A1 NOVEL DGAT2 INHIBITORS DGAT2, DGAT1, LCAT MAP2K7 4186/4885DGAT2 1/4885LTA4H 1212/4885
US-10053429-B2 DGAT2 inhibitors DGAT2, DGAT1, LCAT MAP2K7 4080/4885DGAT2 1/4885LTA4H 1134/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.